DENALI THERAPEUTICS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.36 USD | +5.71% |
|
+13.30% | -9.51% |
Presenter SpeechLaura Hansen (Executives)Good morning, and thank you for joining our webinar t...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinsonâs disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Calendar
2024-05-15
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
18.31
USD
Average target price
38.67
USD
Spread / Average Target
+111.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.51% | 2.61B | |
| +5.26% | 109B | |
| +11.13% | 105B | |
| -0.38% | 22.25B | |
| -11.97% | 22.09B | |
| -7.66% | 18.68B | |
| -36.52% | 17.58B | |
| -10.17% | 16.85B | |
| +3.29% | 13.76B | |
| +36.12% | 12.46B |
- Stock Market
- Equities
- DNLI Stock
- News Denali Therapeutics Inc.
- Transcript : Denali Therapeutics Inc. - Special Call